Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hyaluronic a
cid–doxorubicin
nanoparticles for targeted treatment of colorectal cancer
Authors
Keywords
-
Journal
Bioengineering & Translational Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-13
DOI
10.1002/btm2.10166
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase II trial of aflibercept with FOLFIRI as a 2nd-line treatment for Japanese patients with metastatic colorectal cancer
- (2019) Tadamichi Denda et al. CANCER SCIENCE
- Early colorectal cancer: diagnosis, treatment and survivorship care
- (2019) Gabriella Buccafusca et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Dissecting the Dual Nature of Hyaluronan in the Tumor Microenvironment
- (2019) Muhan Liu et al. Frontiers in Immunology
- Panitumumab Alone for Maintenance Treatment in Advanced Colorectal Cancer
- (2019) Gayathri Anandappa et al. JAMA Oncology
- Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
- (2019) Tetsuya Hamaguchi et al. CANCER SCIENCE
- Adjuvant chemotherapy in resected colon cancer: When, how and how long?
- (2019) Alain J. Gelibter et al. SURGICAL ONCOLOGY-OXFORD
- Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
- (2019) Jesús García-Foncillas et al. Frontiers in Oncology
- Metastatic colorectal cancer: therapeutic options for treating refractory disease
- (2019) A. Parmar et al. Current Oncology
- Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor
- (2018) Song Yi Lee et al. DRUG DELIVERY
- Regorafenib: A Review in Metastatic Colorectal Cancer
- (2018) Sohita Dhillon DRUGS
- The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
- (2018) Julia Martinez-Perez et al. Expert Opinion On Drug Safety
- Targeting p53-dependent stem cell loss for intestinal chemoprotection
- (2018) Brian J. Leibowitz et al. Science Translational Medicine
- Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude
- (2018) Jacob S. Brenner et al. Nature Communications
- Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells
- (2018) Yao-Tseng Chen et al. Oncotarget
- An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
- (2018) Giulia Fornasier et al. ADVANCES IN THERAPY
- Liposomal therapies in oncology: does one size fit all?
- (2018) Isabel Sousa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The safety of ramucirumab for the treatment of colorectal cancer
- (2018) Alba Noguerido et al. Expert Opinion On Drug Safety
- The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer
- (2017) Valentina Mele et al. Oncotarget
- A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
- (2016) Nai-Jung Chiang et al. BMC CANCER
- Carcinoma Cell Hyaluronan as a "Portable" Cancerized Prometastatic Microenvironment
- (2016) E. A. Turley et al. CANCER RESEARCH
- The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer
- (2016) Asuncion Diaz-Serrano et al. Expert Review of Anticancer Therapy
- Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
- (2016) Yi-Nan Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Inflammatory networks underlying colorectal cancer
- (2016) Audrey Lasry et al. NATURE IMMUNOLOGY
- Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
- (2016) Jordan E Axelrad et al. WORLD JOURNAL OF GASTROENTEROLOGY
- PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
- (2016) Benoist Chibaudel et al. Cancer Medicine
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
- (2016) Helena Verdaguer et al. Therapeutic Advances in Medical Oncology
- Role of Biologics in First-Line Treatment of Colorectal Cancer
- (2016) Amit Mahipal et al. Journal of Oncology Practice
- Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
- (2015) T. C. Chang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer
- (2015) Bengt Gustavsson et al. Clinical Colorectal Cancer
- Aflibercept: A Review in Metastatic Colorectal Cancer
- (2015) Yahiya Y. Syed et al. DRUGS
- Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
- (2015) Edouard Alphandéry et al. Expert Review of Anticancer Therapy
- TAS-102 for the treatment of metastatic colorectal cancer
- (2015) Lisa Salvatore et al. Expert Review of Anticancer Therapy
- Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers
- (2015) Viktor Hendrik Koelzer et al. HUMAN PATHOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- (2015) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic antitumor activity of camptothecin–doxorubicin combinations and their conjugates with hyaluronic acid
- (2015) Kathryn M. Camacho et al. JOURNAL OF CONTROLLED RELEASE
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
- (2015) Ken-ichi Fujita WORLD JOURNAL OF GASTROENTEROLOGY
- Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer
- (2015) Suniti Misra et al. Frontiers in Immunology
- The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model
- (2014) M Hoyle et al. HEALTH TECHNOLOGY ASSESSMENT
- Radiation enteropathy—pathogenesis, treatment and prevention
- (2014) Martin Hauer-Jensen et al. Nature Reviews Gastroenterology & Hepatology
- Role of cetuximab in first-line treatment of metastatic colorectal cancer
- (2014) Miguel Jhonatan Sotelo WORLD JOURNAL OF GASTROENTEROLOGY
- Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation
- (2014) Chun Seng Lee WORLD JOURNAL OF GASTROENTEROLOGY
- Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis
- (2014) Eun Ran Kim WORLD JOURNAL OF GASTROENTEROLOGY
- Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen through Adsorption on Red Blood Cells
- (2013) Aaron C. Anselmo et al. ACS Nano
- Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
- (2013) Katherine A. Lyseng-Williamson et al. BIODRUGS
- PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse
- (2012) Hiroaki Konishi et al. BMC CANCER
- Targeted Therapy for Metastatic Colorectal Cancer: Role of Aflibercept
- (2012) Edith P. Mitchell Clinical Colorectal Cancer
- Colitis and Colorectal Cancer
- (2012) Sebastian Foersch et al. DIGESTIVE DISEASES
- Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development
- (2012) Samy A. Azer EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- iNOS-selective inhibitors for cancer prevention: promise and progress
- (2012) Naveena B Janakiram et al. Future Medicinal Chemistry
- Imaging of complications of oncological therapy in the gastrointestinal system
- (2012) Chitra Viswanathan et al. CANCER IMAGING
- Pegylated Liposomal Doxorubicin
- (2011) Sean T. Duggan et al. DRUGS
- Intestinal Inflammation and Cancer
- (2011) Thomas A. Ullman et al. GASTROENTEROLOGY
- Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer
- (2011) Mariko Kambe et al. International Journal of Clinical Oncology
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study
- (2011) B. Chibaudel et al. ONCOLOGIST
- Dysplasia and cancer in inflammatory bowel disease
- (2011) Robert J Basseri et al. Expert Review of Gastroenterology & Hepatology
- Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome
- (2010) Jesús García-Foncillas et al. Clinical & Translational Oncology
- Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer
- (2010) Milan Lukas DIGESTIVE DISEASES
- Inflammation and Colon Cancer
- (2010) Janoš Terzić et al. GASTROENTEROLOGY
- Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis
- (2010) G. Masi et al. JNCI-Journal of the National Cancer Institute
- A physiological approach to modernize the management of cancer chemotherapy-induced gastrointestinal toxicity
- (2010) H Jervoise N Andreyev Current Opinion in Supportive and Palliative Care
- Role of oxaliplatin in the treatment of colorectal cancer
- (2010) Pasquale Comella Therapeutics and Clinical Risk Management
- MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer
- (2009) S. Afzal et al. ANNALS OF ONCOLOGY
- Inflammation and colorectal cancer
- (2009) Sarah Kraus et al. CURRENT OPINION IN PHARMACOLOGY
- Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
- (2009) George P. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of COX-2 in intestinal inflammation and colorectal cancer
- (2009) D Wang et al. ONCOGENE
- Spotlight on Bevacizumab in Metastatic Colorectal Cancer†
- (2008) Paul L McCormack et al. BIODRUGS
- Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point
- (2008) N. Arber CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis
- (2008) I. Zlobec et al. CLINICAL CANCER RESEARCH
- Bevacizumab
- (2008) Paul L McCormack et al. DRUGS
- Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer
- (2008) I Zlobec et al. GUT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started